Pharmafile Logo
Pharmafocus logo
Advanced Search

leukaemia

Showing 15 posts of 89 posts found.

FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths

February 21, 2019
Research and Development Cancer, FDA, Xencor, leukaemia, pharma

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …

News

BMS scores expanded European approval for Sprycel in paediatric leukaemia

February 13, 2019
Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma

Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …

News

Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia

January 29, 2019
Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma

It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …

News
amgen_hq

Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia

January 23, 2019
Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma

The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …

News

Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE

January 18, 2019
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma

A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

News
abbvie_0

AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma

AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …

News

Novartis unveils strong longer-term Kymriah data at ASH 2018

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …

News

Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia

November 22, 2018
Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia

Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …

News

Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund

November 15, 2018
Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …

News
acute_lymphoblastic_leukaemia_smear

Azacitidine and nivolumab combo proves successful in phase II trial

November 13, 2018
Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas

A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …

News

Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma

November 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Mundipharma, Philippe Bastide, biosimilars, leukaemia

“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …

Feature

NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia

October 26, 2018
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, leukaemia, pharma, venetoclax

It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health …

News

NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia

October 8, 2018
Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma

NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …

News
acute_lymphoblastic_leukaemia_smear

20 year old man died after leukaemia cell was accidently mixed into CAR T therapy

October 2, 2018
Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology

A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023